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Background
The second messenger cGMP plays a central role in regu-
lating bodily functions, e.g. in the cardiovascular and
nervous systems. cGMP is formed by guanylyl cyclases
(GC), activates target proteins, and is finally hydrolyzed
by cyclic nucleotide phosphodiesterases (PDE). PDEs and
GCs are widely used as drug targets, spurring interest in
mechanistic and structural insights into their regulation.
Different to the closely GC-related Class III adenylyl cycla-
ses, until recently no structures of eukaryotic GCs could be
obtained and all bacterial Class III proteins were found to
be ACs rather than GCs. For PDEs, in contrast, a wealth of
structures of their catalytic domains is available. However,
first structures of regulatory GAF domains present in sev-
eral PDEs gave contradictory results on their assembly and
function, so that further structural data are needed for a
complete understanding.
Results
We could show that the cyanobacterial Class III cyclase
Cya2 shows high specificity for GTP versus ATP, revealing
it to be the first bacterial GC [1]. We solved the crystal
structure of Cya2, providing first structural insights into
the universal GC family. Structure and mutagenesis stud-
ies show that a conserved glutamate, assisted by an inter-
acting lysine, dominates substrate selection by forming
hydrogen bonds to the substrate base. We find, however,
that a second residue involved in substrate selection has
an unexpected sterical role in GCs. Further structural dif-
ferences and kinetic data indicate the molecular basis of
substrate recognition and sensitivity to non-competitive
cyclase inhibitors [2], giving hints for the development of
specific GC inhibitors.
We further solved the crystal structure of the central GAF
domain of a mammalian PDE5 (manuscript in prepara-
tion). The dimerization mode of the isolated domain
indicates how the holoenzyme dimer is assembled, and
the hydrohpbic interaction interface suggests a model for
the mechanism of activation of PDE5 through ligand
binding to the neighbouring GAF domain.
Conclusion
We could identify Cya2 as the first bacterial GC, and
sequence similarity searches suggest that GCs are also
present in other bacteria. Structural and biochemical data
on this model system for mammalian GCs indicate mech-
anisms for substrate binding and recognition and for
inhibitor sensitivity, giving hints for the development of
GC-specific inhibitors. Our structural data on the PDE5
GAF domain further indicate a model for PDE5 assembly
and activation, increasing our understanding of this ele-
ment within the cyclic nucleotide signalling system and
helping further drug development efforts against this tar-
get.
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